SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

by · The Cerbat Gem

SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 37,000 shares, an increase of 38.6% from the November 30th total of 26,700 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average trading volume of 24,300 shares, the short-interest ratio is currently 1.5 days.

SOPHiA GENETICS Stock Up 5.3 %

SOPH traded up $0.17 during trading hours on Friday, hitting $3.36. 63,955 shares of the company’s stock were exchanged, compared to its average volume of 62,102. The stock has a market cap of $219.66 million, a price-to-earnings ratio of -3.08 and a beta of 0.99. SOPHiA GENETICS has a 1-year low of $2.70 and a 1-year high of $7.37. The stock’s 50-day moving average is $3.39 and its two-hundred day moving average is $3.83. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative return on equity of 55.06% and a negative net margin of 110.71%. The business had revenue of $15.85 million for the quarter, compared to analyst estimates of $15.90 million. During the same quarter in the prior year, the company earned ($0.21) earnings per share. Sell-side analysts predict that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the stock. Banque Cantonale Vaudoise raised its position in SOPHiA GENETICS by 300.0% during the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after acquiring an additional 9,000 shares in the last quarter. Green Alpha Advisors LLC bought a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at about $79,000. Federated Hermes Inc. increased its stake in shares of SOPHiA GENETICS by 57.5% during the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock worth $289,000 after purchasing an additional 23,000 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of SOPHiA GENETICS by 35.9% during the 2nd quarter. Principal Financial Group Inc. now owns 1,368,378 shares of the company’s stock worth $6,267,000 after purchasing an additional 361,201 shares during the last quarter. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

Separately, Craig Hallum started coverage on SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.40.

Get Our Latest Analysis on SOPHiA GENETICS

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.

Featured Stories